Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | POLB | P06746 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28841606 | 0.92 | ALDH1A1 (0.73) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL23412417 | 0.92 | ALDH1A1 (0.76) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL19034437 | 0.86 | ALDH1A1 (1.00) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL7150270 | 0.85 | ALDH1A1 (0.76) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL11244847 | 0.85 | ALDH1A1 (0.76) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL17512401 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL6813418 | 0.81 | MEN1 (0.73) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL6813402 | 0.81 | ALDH1A1 (0.77) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL28741147 | 0.80 | ALDH1A1 (0.67) | ALDH1A1CYP3A4TSHRTDP1MEN1 | |
| SCHEMBL29639193 | 0.80 | ALDH1A1 (0.67) | ALDH1A1CYP3A4TSHRTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067608-B2 | Hedgehog pathway antagonists | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067608-B2 | Hedgehog pathway antagonists | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20070232661-A1 | Hedgehog Pathway Antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-10-04 | — | — | US | disclosed |
| US-20070232661-A1 | Hedgehog Pathway Antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232661-A1 | Hedgehog Pathway Antagonists | GLI1, SHH, SMO | ALDH1A1 1802/4885CYP3A4 4865/4885TSHR 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.